Beyond Air (XAIR) Scheduled to Post Earnings on Monday

Beyond Air (NASDAQ:XAIR) will announce its earnings results after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.12. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.72 million. Beyond Air had a negative net margin of 3,272.46% and a negative return on equity of 240.15%. During the same period last year, the company posted ($0.45) earnings per share. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Beyond Air Stock Down 14.0 %

Beyond Air stock opened at $0.49 on Monday. The company has a quick ratio of 2.42, a current ratio of 2.63 and a debt-to-equity ratio of 0.84. The firm has a market cap of $23.13 million, a P/E ratio of -0.30 and a beta of -0.18. The business has a fifty day moving average of $0.40 and a two-hundred day moving average of $0.72. Beyond Air has a twelve month low of $0.30 and a twelve month high of $2.61.

Insider Activity at Beyond Air

In other Beyond Air news, CEO Steven A. Lisi purchased 100,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was acquired at an average price of $0.39 per share, with a total value of $39,000.00. Following the completion of the acquisition, the chief executive officer now owns 1,722,785 shares in the company, valued at $671,886.15. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Steven A. Lisi purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average price of $0.39 per share, with a total value of $39,000.00. Following the completion of the acquisition, the chief executive officer now owns 1,722,785 shares in the company, valued at approximately $671,886.15. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Steven A. Lisi acquired 1,476,626 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $738,313.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at approximately $1,624,705.50. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 1,615,892 shares of company stock valued at $793,019 in the last ninety days. Corporate insiders own 19.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on XAIR shares. Roth Capital raised Beyond Air to a “strong-buy” rating in a research report on Friday, August 16th. Roth Mkm restated a “buy” rating and issued a $2.00 price target on shares of Beyond Air in a report on Friday, August 16th. Finally, Piper Sandler cut their price objective on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $3.67.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.